Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Detection of Microsatellite Instability Biomarkers via Next-Generation Sequencing.

Bonneville R, Krook MA, Chen HZ, Smith A, Samorodnitsky E, Wing MR, Reeser JW, Roychowdhury S.

Methods Mol Biol. 2020;2055:119-132. doi: 10.1007/978-1-4939-9773-2_5.

PMID:
31502149
2.

Tumor heterogeneity and acquired drug resistance in FGFR2-fusion-positive cholangiocarcinoma through rapid research autopsy.

Krook MA, Bonneville R, Chen HZ, Reeser JW, Wing MR, Martin DM, Smith AM, Dao T, Samorodnitsky E, Paruchuri A, Miya J, Baker KR, Yu L, Timmers C, Dittmar K, Freud AG, Allenby P, Roychowdhury S.

Cold Spring Harb Mol Case Stud. 2019 Aug 1;5(4). pii: a004002. doi: 10.1101/mcs.a004002. Print 2019 Aug.

3.

Characterization of a KLK2-FGFR2 fusion gene in two cases of metastatic prostate cancer.

Krook MA, Barker H, Chen HZ, Reeser JW, Wing MR, Martin D, Smith AM, Dao T, Bonneville R, Samorodnitsky E, Miya J, Freud AG, Monk JP, Clinton SK, Roychowdhury S.

Prostate Cancer Prostatic Dis. 2019 Dec;22(4):624-632. doi: 10.1038/s41391-019-0145-2. Epub 2019 May 1.

4.

Microsatellite Instability Occurs in a Subset of Follicular Thyroid Cancers.

Genutis LK, Tomsic J, Bundschuh RA, Brock PL, Williams MD, Roychowdhury S, Reeser JW, Frankel WL, Alsomali M, Routbort MJ, Broaddus RR, Wakely PE Jr, Phay JE, Walker CJ, de la Chapelle A.

Thyroid. 2019 Apr;29(4):523-529. doi: 10.1089/thy.2018.0655. Epub 2019 Mar 27.

PMID:
30747051
5.

Genomic characterization of metastatic ultra-hypermutated interdigitating dendritic cell sarcoma through rapid research autopsy.

Chen HZ, Bonneville R, Yu L, Wing MR, Reeser JW, Krook MA, Miya J, Samorodnitsky E, Smith A, Martin D, Dao T, Guo Q, Liebner D, Freud AG, Allenby P, Roychowdhury S.

Oncotarget. 2019 Jan 8;10(3):277-288. doi: 10.18632/oncotarget.26352. eCollection 2019 Jan 8.

6.

Targeting BRAF Mutations in High-Grade Neuroendocrine Carcinoma of the Colon.

Burkart J, Owen D, Shah MH, Abdel-Misih SRZ, Roychowdhury S, Wesolowski R, Haraldsdottir S, Reeser JW, Samorodnitsky E, Smith A, Konda B.

J Natl Compr Canc Netw. 2018 Sep;16(9):1035-1040. doi: 10.6004/jnccn.2018.7043.

PMID:
30181415
7.

Metaplastic breast cancer in a patient with neurofibromatosis type 1 and somatic loss of heterozygosity.

Suarez-Kelly LP, Akagi K, Reeser JW, Samorodnitsky E, Reeder M, Smith A, Roychowdhury S, Symer DE, Carson WE.

Cold Spring Harb Mol Case Stud. 2018 Apr 2;4(2). pii: a002352. doi: 10.1101/mcs.a002352. Print 2018 Apr. Review.

8.

Analytic validation and real-time clinical application of an amplicon-based targeted gene panel for advanced cancer.

Wing MR, Reeser JW, Smith AM, Reeder M, Martin D, Jewell BM, Datta J, Miya J, Monk JP, Mortazavi A, Otterson GA, Goldberg RM, VanDeusen JB, Cole S, Dittmar K, Jaiswal S, Kinzie M, Waikhom S, Freud AG, Zhou XP, Chen W, Bhatt D, Roychowdhury S.

Oncotarget. 2017 Sep 1;8(44):75822-75833. doi: 10.18632/oncotarget.20616. eCollection 2017 Sep 29.

9.

Trametinib for the treatment of IGHV4-34, MAP2K1-mutant variant hairy cell leukemia.

Andritsos LA, Grieselhuber NR, Anghelina M, Rogers KA, Roychowdhury S, Reeser JW, Timmers CD, Freud AG, Blachly JS, Lucas DM, Lozanski G, Jones JA, Williams K, Oakes C, Jones D, Grever MR.

Leuk Lymphoma. 2018 Apr;59(4):1008-1011. doi: 10.1080/10428194.2017.1365853. Epub 2017 Sep 18. No abstract available.

PMID:
28918710
10.

Validation of a Targeted RNA Sequencing Assay for Kinase Fusion Detection in Solid Tumors.

Reeser JW, Martin D, Miya J, Kautto EA, Lyon E, Zhu E, Wing MR, Smith A, Reeder M, Samorodnitsky E, Parks H, Naik KR, Gozgit J, Nowacki N, Davies KD, Varella-Garcia M, Yu L, Freud AG, Coleman J, Aisner DL, Roychowdhury S.

J Mol Diagn. 2017 Sep;19(5):682-696. doi: 10.1016/j.jmoldx.2017.05.006. Epub 2017 Aug 9.

11.

Akt Activation Mediates Acquired Resistance to Fibroblast Growth Factor Receptor Inhibitor BGJ398.

Datta J, Damodaran S, Parks H, Ocrainiciuc C, Miya J, Yu L, Gardner EP, Samorodnitsky E, Wing MR, Bhatt D, Hays J, Reeser JW, Roychowdhury S.

Mol Cancer Ther. 2017 Apr;16(4):614-624. doi: 10.1158/1535-7163.MCT-15-1010. Epub 2017 Mar 2.

12.

Landscape of Microsatellite Instability Across 39 Cancer Types.

Bonneville R, Krook MA, Kautto EA, Miya J, Wing MR, Chen HZ, Reeser JW, Yu L, Roychowdhury S.

JCO Precis Oncol. 2017;2017. doi: 10.1200/PO.17.00073. Epub 2017 Oct 3.

13.

Performance evaluation for rapid detection of pan-cancer microsatellite instability with MANTIS.

Kautto EA, Bonneville R, Miya J, Yu L, Krook MA, Reeser JW, Roychowdhury S.

Oncotarget. 2017 Jan 31;8(5):7452-7463. doi: 10.18632/oncotarget.13918.

14.

Targeted RNA Sequencing Assay to Characterize Gene Expression and Genomic Alterations.

Martin DP, Miya J, Reeser JW, Roychowdhury S.

J Vis Exp. 2016 Aug 4;(114). doi: 10.3791/54090.

15.

Cancer Driver Log (CanDL): Catalog of Potentially Actionable Cancer Mutations.

Damodaran S, Miya J, Kautto E, Zhu E, Samorodnitsky E, Datta J, Reeser JW, Roychowdhury S.

J Mol Diagn. 2015 Sep;17(5):554-9. doi: 10.1016/j.jmoldx.2015.05.002.

16.

Evaluation of Hybridization Capture Versus Amplicon-Based Methods for Whole-Exome Sequencing.

Samorodnitsky E, Jewell BM, Hagopian R, Miya J, Wing MR, Lyon E, Damodaran S, Bhatt D, Reeser JW, Datta J, Roychowdhury S.

Hum Mutat. 2015 Sep;36(9):903-14. doi: 10.1002/humu.22825. Epub 2015 Jul 15.

17.

Comparison of custom capture for targeted next-generation DNA sequencing.

Samorodnitsky E, Datta J, Jewell BM, Hagopian R, Miya J, Wing MR, Damodaran S, Lippus JM, Reeser JW, Bhatt D, Timmers CD, Roychowdhury S.

J Mol Diagn. 2015 Jan;17(1):64-75. doi: 10.1016/j.jmoldx.2014.09.009.

Supplemental Content

Loading ...
Support Center